RARE241220C40000
- 12.60
- 0.000.00%
Ultragenyx Pharmaceutical Newsroom
Ultragenyx Pharmaceutical Analyst Ratings
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $102
Express News | Ultragenyx Pharmaceutical Inc : JP Morgan Cuts Target Price to $102 From $105
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $121
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Posts Trial Data Backing Phase 3 Design for Angelman Syndrome Therapy
Express News | Ultragenyx Presents Positive Update on Gtx-102 Angelman Syndrome Program at Fast’s 17TH Annual Global Science Summit
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $70 to $135
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
Ultragenyx Pharmaceutical | 10-Q: Q3 2024 Earnings Report
Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity
RBC Capital Reiterates Outperform on Ultragenyx Pharmaceutical, Maintains $77 Price Target
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates